Granted Patent
B2
US 10,280,150 · App. 15/712,446 · Granted May 7, 2019
Quinolinone pyrimidines compositions as mutant-isocitrate dehydrogenase inhibitors
Inventors:
Jian Lin (Acton, MA); Anna Ericsson (Shrewsbury, MA); Ann-Marie Campbell (Monroe, CT); Gary Gustafson (Ridgefield, CT); Zhongguo Wang (Lexington, MA); R. Bruce Diebold (Waltham, MA); Susan Ashwell (Carlisle, MA); David R. Lancia, Jr. (Boston, MA); Justin Andrew Caravella (Cambridge, MA); Wei Lu (Newton, MA)
Assignee:
FORMA TM2, INC.
View Patent ↗
Loading inventors, assignments & file history…
Abstract
The invention relates to inhibitors of mutant isocitrate dehydrogenase (mt-IDH) proteins with neomorphic activity useful in the treatment of cell-proliferation disorders and cancers, having the Formula: where A, B, W 1 , W 2 , W 3 , and R 1 -R 6 are described herein.
Claims (4)
1. The compound
2-{[(1S)-1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl]amino}-4-methoxypyrimidine-5-carbonitrile, or a pharmaceutically acceptable salt thereof.
2. A pharmaceutical composition comprising the compound:
or a pharmaceutically acceptable salt thereof.
Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Jun 26, 2019
From: FORMA TM2, INC.
To: FORMA THERAPEUTICS, INC.
Reel/Frame 049598/0522 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Nov 8, 2018
From: FORMA THERAPEUTICS, INC.
To: FORMA TM2, INC.
Reel/Frame 047457/0946 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Jan 4, 2018
From: LIN, JIAN; ERICSSON, ANNA; CAMPBELL, ANN-MARIE; GUSTAFSON, GARY; WANG, ZHONGGUO; DIEBOLD, R. BRUCE; ASHWELL, SUSAN; LANCIA, DAVID R., JR.; CARAVELLA, JUSTIN ANDREW; LU, WEI
To: FORMA THERAPEUTICS, INC.
Reel/Frame 044540/0674 →
Continuity (3)
Provisional Application
62053010
· Sep 19, 2014
Cited By (1)